AMP-activated protein kinase signaling in metabolic regulation.

By Y. Long, J. Zierath. Journal of Clinical Investigation, 2006

1,032 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. (2008, background): “Figure 1 Leptin and adiponectin: leptin acts primarily via the melanocortin system (arcuate nucleus) in the hypothalamus(15) where it inhibits 5’AMP-activated protein kinase,(20) resulting in decreased hunger and stimulated energy expenditure(8,17) and, to a lesser extent, in enhancing growth (growt”
AMPK: an emerging drug target for diabetes and the metabolic syndrome. (2009, background): “These findings, coupled with reports that AMPK in muscle is activated in response to exercise (Long and Zierath, 2006; Reznick and Shulman, 2006), have led to an intense interest in developing AMPK activators as potential therapies for T2DM and obesity (Hardie, 2008).”
Metformin Induces a Dietary Restriction–Like State and the Oxidative Stress Response to Extend C. elegans Healthspan via AMPK, LKB1, and SKN-1 (2010, background): “How is AMPK likely to promote DR-like metabolism? In mammals, there are several known AMPK targets that modulate metabolic pathways including those responsible for fatty acid, protein, and cholesterol synthesis, as well as those that mediate glucose transport and glycolysis in liver and muscle [77,7”